Juliana Schwaab

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Alice Fabarius, Armin Leitner, Andreas Hochhaus et al. · Blood · 2011 · 290 citations

Life Sciences, Genetics, Hematology +16

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Barbara Peter, Georg E. Winter, K. Blatt et al. · Leukemia · 2015 · 60 citations · Full text

Medicine, Oncology, Pharmacology +14

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

Andrew Chase, Catherine Bryant, J Score et al. · Haematologica · 2012 · 35 citations · Full text

Medicine, Hematology, Oncology +17

Activating CBL mutations are associated with a distinct MDS/MPN phenotype

Juliana Schwaab, Thomas Ernst, Philipp Erben et al. · Annals of Hematology · 2012 · 33 citations

Medicine, Genetics, Molecular Genetics +9

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells

Barbara Peter, Shabana Bibi, Gregor Eisenwort et al. · Leukemia · 2017 · 26 citations

Life Sciences, Cell Biology, Pharmacology +10